January 2025, Vol 15, No 1
On November 20, 2024, officials with the FDA granted accelerated approval to zanidatamab-hrii (Ziihera; Jazz Pharmaceuticals, Inc), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test. Read More ›
On November 19, 2024, the FDA approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection; Sandoz) under Project Renewal, a public health initiative under the Oncology Center of Excellence program, which is designed to update labeling information for certain older oncology drugs to ensure information is clinically meaningful. Read More ›
On December 13, 2024, FDA officials approved cosibelimab-ipdl (Unloxcyt; Checkpoint Therapeutics, Inc), a programmed death ligand-1 (PD-L1)-blocking antibody, for adults with locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation or metastatic cutaneous squamous cell carcinoma. Read More ›
A regular column that features the 2024 approvals and updates from the Food and Drug Administration. Read More ›
By Maimah Karmo
As a healthcare provider, you play a crucial role in connecting patients to
life-changing resources that offer more than medical care—you provide hope, empowerment, and community. Read More ›